Literature DB >> 21937626

Parathyroid carcinoma: a 43-year outcome and survival analysis.

Avital Harari1, Avantika Waring, Gustavo Fernandez-Ranvier, Jimmy Hwang, Insoo Suh, Elliot Mitmaker, Wen Shen, Jessica Gosnell, Quan-Yang Duh, Orlo Clark.   

Abstract

CONTEXT: Parathyroid carcinoma is a rare but ominous cause of primary hyperparathyroidism. OBJECTIVES AND MAIN OUTCOME MEASURES: The objective of the study was to review the outcomes of parathyroid cancer patients and to evaluate the factors associated with mortality. DESIGN, SETTING, AND PATIENTS: This was a retrospective review performed on 37 patients with parathyroid cancer treated at a single university tertiary care center between 1966 and 2009.
RESULTS: The average age at cancer diagnosis was 53 yr (range 23-75 yr), and 23 patients (62%) were men. Eighteen patients (49%) recurred after their initial cancer operation. The average number of neck dissections done for cancer was three (range 1-11). After initial diagnosis, 22 patients (60%) eventually developed complications, including unilateral (n = 11) or bilateral (n = 3) vocal cord paralysis (38%). Eight patients (22%) had, at some point, an associated benign parathyroid adenoma. Median overall survival was 14.3 yr (range 10.5-25.7 yr) from the date of diagnosis. Factors associated with increased mortality included lymph node or distant metastases, number of recurrences, higher calcium level at recurrence, and a high number of calcium-lowering medications. Factors not associated with mortality included age, race, tumor size, time to first recurrence, and extent of initial operation. Initial operations done at our center had improved survival (P = 0.037) and decreased complication rates (P < 0.001) vs. those done elsewhere.
CONCLUSION: Parathyroid cancer patients typically have a long survival, which often includes multiple reoperations for recurrence and thus a high rate of surgical complications. Patients in whom there is a high index of suspicion for parathyroid cancer should be referred to a dedicated endocrine surgery center for their initial operation.

Entities:  

Mesh:

Year:  2011        PMID: 21937626     DOI: 10.1210/jc.2011-1571

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  63 in total

1.  Outcomes of parathyroid cancer--insights from a 43-year period.

Authors:  Carol Wilson
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

2.  Tracheal Resection in Recurrent Parathyroid Carcinoma-a Case Report.

Authors:  Ramya C Valiveru; Sanjay K Yadav; Nandita Chaudhary; Saroj K Mishra
Journal:  Indian J Surg Oncol       Date:  2020-07-25

3.  Non-functioning parathyroid cystic tumour: malignant or not? Report of a case.

Authors:  G Cocorullo; G Scerrino; G Melfa; C Raspanti; G Rotolo; V Mannino; P Richiusa; D Cabibi; A G Giannone; C Porrello; G Gulotta
Journal:  G Chir       Date:  2017 Sep-Oct

4.  Is central lymph node dissection necessary for parathyroid carcinoma?

Authors:  Kun-Tai Hsu; Rebecca S Sippel; Herbert Chen; David F Schneider
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

5.  Epidemiology and prognosis of parathyroid carcinoma: real-world data using nationwide cohort.

Authors:  Sung Hye Kong; Jung Hee Kim; Man Young Park; Sang Wan Kim; Chan Soo Shin
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-18       Impact factor: 4.553

6.  Parathyroid carcinoma, a rare cause of primary hyperparathyroidism.

Authors:  Adam Alperstein; Rajendra Bhayani
Journal:  BMJ Case Rep       Date:  2014-08-19

7.  Tumor Size and Presence of Metastatic Disease at Diagnosis are Associated with Disease-Specific Survival in Parathyroid Carcinoma.

Authors:  Winifred M Lo; Meghan L Good; Naris Nilubol; Nancy D Perrier; Dhaval T Patel
Journal:  Ann Surg Oncol       Date:  2018-07-03       Impact factor: 5.344

Review 8.  Endocrine neoplasms in familial syndromes of hyperparathyroidism.

Authors:  Yulong Li; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2016-05-20       Impact factor: 5.678

9.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

10.  Parathyroid Carcinoma in Patients that Have Undergone Surgery for Primary Hyperparathyroidism.

Authors:  Petr Libánský; Svatopluk Adámek; Petr Broulík; Martina Fialová; Josef Kubinyi; Robert Lischke; Ondřej Naňka; Pavel Pafko; Jiří Šedý; Vladimír Bobek
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.